Navigation Links
Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
Date:11/8/2011

in-stent late lumen loss of 0.03 mm at four months, 0.10 mm at six months and 0.08 mm at eight months follow-up with no binary restenosis or revascularizations. The mean in-stent late lumen loss values at four, six and eight months were 0.01, 0.21 and 0.09 mm, respectively. The mean and median values were comparable except at the six month time point, in which one patient experienced a high late loss value due to treatment of a highly calcified lesion and under-expansion of the stent. When data from this patient is excluded, the six month mean LLL is 0.10 mm. The median percent of stent struts covered by tissue was 96% at eight months, 97% at six months and 90% at four months per OCT analysis. IVUS confirmed good inhibition of neointimal hyperplasia. A MACE rate of 6.7%, including two non-Q wave myocardial infarctions (MI), one peri-procedural and one non-target vessel MI, was reported through eight months follow-up.

"The MiStent DES was designed to address a need for improved patient safety while providing equivalent or better efficacy as compared to currently available drug eluting stents," observed Dennis Donohoe, M.D., Chief Medical Advisor to Micell. "The excellent clinical outcomes of the DESSOLVE I trial demonstrate the value of the MiStent design in enabling elimination of drug and polymer from the stent in 45 to 60 days and providing patients the best of DES and BMS in one solution."

About DESSOLVE I and DESSOLVE II Studies

The DESSOLVE I trial, the first clinical assessment of safety and efficacy of the MiStent DES, treated thirty patients with de novo lesions in coronary arteries ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm length stent. Subjects were enrolled across five study centers in New Zealand, Australia and Belgium. Three independent subgroups of 10 patients each were evaluated using angiography, IVUS and OCT at three time points: four, six and eight months. The pr
'/>"/>

SOURCE Micell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micell Technologies Announces Presentation of Clinical Data at TCT 2011
2. Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent® Drug-Eluting Coronary Stent
3. Micell Technologies Announces Reduced Clinical Trial Sample Size for MiStent® Drug-Eluting Coronary Stent Based on Early Clinical Data
4. Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
5. BioMarCare Technologies Ltd. Granted Access to Archived Samples in the Hadassah Medical Center
6. Medisafe 1 Technologies Pre-pays Additional 2 Convertible Promissory Notes Due in Full to Avoid Dilution to Shareholders
7. Filtrona Porous Technologies to Introduce New Hydrophilic Foam Products for Advanced Wound Care at the MEDICA / COMPAMED Trade Fair
8. China Medical Technologies to Announce Results for the Second Fiscal Quarter Ended September 30, 2011 on November 18, 2011
9. AquaLiv Technologies Subsidiary AquaLiv, Inc. Discusses Registration In Kenya Concerning Its HIV/AIDS Treatment
10. The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion
11. Connectyx Technologies to Host Teleconference on Third Quarter Financial Results on Tuesday November 15, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Varian Medical Systems (NYSE: VAR ) ... U.S. Customs and Border Protection (CBP) for multiple IntellX® cargo ... company,s largest single order for Varian,s IntellX gantry systems. The ... vehicles for both border security and manifest verification purposes. ...
... 2011 DURECT Corporation (Nasdaq: DRRX ) ... (FDA) has accepted the resubmission of the New Drug ... KG ) and the PDUFA goal date ... ) REMOXY, based on DURECT,s ORADUR® technology, ...
Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 3
(Date:7/11/2014)... 12, 2014 According to new ... market is expected to register a CAGR of ... Browse 71 market data tables and 76 figures ... "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early buyers ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market analysis ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- People with the lowest ... called peripheral artery disease (PAD), a new study suggests. ... blood to the limbs, most often the legs. The condition ... of the arteries throughout the body. People with PAD have ... analyzed data from nearly 6,800 people with PAD who took ...
(Date:7/11/2014)... 11, 2014 The report, “Specialty ... Applications & Geography - 2018,” defines and segments ... with an analysis and forecast of the volumes ... fibers (Para aramids, meta aramids, UHMW Polyethylene, carbon ... PPS fiber, PBI fiber, PBO fiber, and liquid ...
(Date:7/11/2014)... -- In people with sex addiction, pornography affects the ... in drug addicts as they consume drugs, a new ... activity between patients who have compulsive sexual behavior and ... study author Dr. Valerie Voon, of the University of ... Voon,s research involved 19 men with sex addiction ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, Inc. ... to cell and gene therapies for cancer – ... organization as Senior Development Officer. , Corday is ... gifts and addressing influential donors. Prior to joining ... NewYork Presbyterian Hospital/Columbia University Medical Center, where he ...
Breaking Medicine News(10 mins):Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3
... , , , ... females, a team of Ohio physicians representing the Women,s Dermatologic ... safety education for tennis fans enjoying the Western & Southern ... Saturday, August 15, from 9:00 a.m.-5:00 p.m. Led by board-certified dermatologist ...
... 10 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") (Nasdaq: ... products and services in the People,s Republic of China, ... multi-year distribution,agreements for China with Biotest AG and Cutera ... in Dreieich, Germany (SDAX: BIO3), specializes in,innovative hematology and ...
... , , ANN ARBOR, Mich., ... U.S. health systems based on their hospitals, clinical performance. They are: , , ... , Catholic Healthcare Partners -- Cincinnati, OH , ... HealthEast Care System -- Saint Paul, MN , Henry ...
... PHILADELPHIA, Pennsylvania, August 10 , ... Improve Patient Care, Help,Prevent Costly Mistakes; Hospitals Benefit From ... a world leader in healthcare and medical publishing and ... tool within,Mosby,s Nursing Consult designed to help nurses prevent ...
... ... Enhances Innovative Solutions for Travelers and Individuals , ... Indianapolis, IN (PRWEB) August 10, 2009 ... insurance, today announced it has signed an agreement with Eldorado Computing, Inc. (Eldorado) ...
... ... balance, confidence and quality of life. , ... Hamilton, AL (PRWEB) Jeanne Crace, 70, who has five daughters, ... Parkinson,s disease. , , , , ,Parkinson,s Disease remains a mystery of medical ...
Cached Medicine News:Health News:Ohio Dermatologists to Help Tennis Community Get Into the Swing of Sun Safety 2Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 2Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 3Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 4Health News:Thomson Reuters Research Identifies Top U.S. Health Systems 2Health News:Thomson Reuters Research Identifies Top U.S. Health Systems 3Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 2Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 3Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 4Health News:HCC Medical Insurance Services Selects Eldorado's Innovative Claims & Benefits Platform 2Health News:Exploring Newly Found Freedom with the GaitAid for Parkinson's Disease 2Health News:Exploring Newly Found Freedom with the GaitAid for Parkinson's Disease 3
They employ Lea Symbols. Contrast levels are the same at 25%, 10%, 5%, 2.5% and 1.25%. Each offers a different set of Lea Symbols to guard against memorization. Also uses recording forms (P/N 215400)...
Symbol 10' Test Chart 10/100 to 10/10 size. 9" x 14"....
Wilbrandt-binkhorst irrigating cannula....
Binkhorst, length 35 mm....
Medicine Products: